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Abstract: The enzyme vascular non-inflammatory molecule-1 (vanin 1) is highly expressed at gene
and protein level in many organs, such as the liver, intestine, and kidney. Its major function is
related to its pantetheinase activity; vanin 1 breaks down pantetheine in cysteamine and pantothenic
acid, a precursor of coenzyme A. Indeed, its physiological role seems strictly related to coenzyme A
metabolism, lipid metabolism, and energy production. In recent years, many studies have elucidated
the role of vanin 1 under physiological conditions in relation to oxidative stress and inflammation.
Vanin’s enzymatic activity was found to be of key importance in certain diseases, either for its
protective effect or as a sensitizer, depending on the diseased organ. In this review, we discuss the role
of vanin 1 in the liver, kidney, intestine, and lung under physiological as well as pathophysiological
conditions. Thus, we provide a more complete understanding and overview of its complex function
and contribution to some specific pathologies.
Keywords: vanin 1; oxidative stress; PPAR-alpha; PPAR-gamma; urinary biomarker; pro-inflammatory
role; protective role
Vascular non-inflammatory molecule-1, in short vanin 1, is an ectoenzyme with pantetheinase
activity [1]. It is highly expressed at the gene and protein level in many organs, such as the liver,
intestine, and kidney. Its major function is related to its pantetheinase activity, as follows: Vanin 1
breaks down pantetheine into cysteamine and pantothenic acid, a precursor of coenzyme A. Indeed,
its physiological role seems strictly related to coenzyme A metabolism, lipid metabolism, and energy
production. In recent years, many studies have elucidated the role of vanin 1 under physiological
conditions in relation to oxidative stress and inflammation. Vanin’s enzymatic activity was found to be
of key importance in certain diseases, either for its protective effect or as a sensitizer, depending on
the diseased organ. In this review, we discuss the role of vanin 1 in the liver, kidney, intestine, and
lung under physiological as well as pathophysiological conditions. Thus, we provide a more complete
understanding and overview of its complex function and contribution to some specific pathologies.
Vanin 1 was first identified as a novel surface molecule involved in thymus homing of bone
marrow cells in mice; yet, sequence analysis of vanin 1 showed no homology with other adhesion
proteins [1]. Two human counterparts of the murine Vnn1 gene (mVnn1), hVnn1, and hVnn2, were
identified later, sharing 78% and 64% of sequence identity with mVnn1, respectively [2]. Recently, the
3D structure of human vanin 1 confirmed the presence of a nitrilase domain conferring enzymatic
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activity (PDB code 4CYF) [3]. In addition, the structure revealed the presence of a base domain which
could be involved in cellular adherence and homing through protein–protein interactions. Though we
do not exclude a potential role for the base domain as a signaling protein, here we focus on vanin’s
pantetheinase activity in different organs.
Vanin 1 is membrane-associated via a glycosylphosphatidylinositol (GPI)-anchor, though soluble
forms of human and mouse vanin 1 have been detected as well [4]. Under physiological conditions,
the mRNA expression of human vanin 1 is particularly high in lung, liver, kidney, gastrointestinal
tract (mainly in the duodenum and jejunum [5]), spleen, blood, and skin [6]. In murine tissues, the
gene expression of vanin 1 is found to be high mainly in the kidney, intestine, and liver [7,8]. hVanin
2 is a GPI-anchored pantetheinase as well, expressed in tissues such as spleen, kidney, and lungs;
however, hVanin 2 shows a much higher expression in the blood than hVanin 1 [6], specifically in
neutrophils [8–10]. Scanning general and organism-specific expressed sequence tag (EST) databases
led to the identification of hVnn3, which maps to the human chromosome 6q22-24 region, as do hVnn1
and hVnn2 [9,11]. hVnn3 appears to encode a truncated protein, suggesting it might be a pseudogene
or encoding a protein other than a pantetheinase [8]. Other vanin molecules include mVanin 3, a rat
vanin 1 orthologue, a drosophila homologue, and bottlenose dolphin vanin 1 [11,12]. mVanin 3 mRNA
has been detected in lung tissue, liver, and blood, while its gene expression is completely absent
in kidney [6,8,9]. Among these genes belonging to the pantetheinase family, murine and human
vanin 1 have been studied best. Here, we provide an overview of vanin 1′s role in physiological and
pathophysiological conditions in different organs.
1. Function, Expression, and Regulation of Vanin 1 Under Physiological Conditions
Vanin 1′s primary function is the recycling of pantothenic acid (vitamin B5), an important
precursor in the biosynthesis of CoenzymeA (CoA); indeed, vanin 1 is highly expressed in tissues with
a high CoA turnover, such as liver, intestine, and kidney [13]. CoA, the cofactor known for its role
in the synthesis and oxidation of fatty acids [14], is assembled in five steps from pantothenic acid,
cysteine and adenosine triphosphate (ATP) [15]. CoA homeostasis is regulated by its biosynthesis,
degradation, and the use of free CoA as a conjugate, e.g., as acyl-CoA. While CoA biosynthesis
has been studied in detail, relatively little is known about CoA degradation, though a number of
enzymes (e.g., nudix hydrolases) are hypothesized to play a role [14,15]. These enzymes consequently
regulate the bioavailability of phosphopantetheine, which in turn is degraded through phosphatase and
pantetheinase activity [16]. This specific enzymatic activity was first observed in crude horse kidney
extracts, in which the oxidized form of pantetheine, pantethine, was converted into pantothenic acid
and cysteamine [17,18]. Pantetheinase activity was also observed in other organs of other mammals,
such as birds, pigs, and rats. Based on sequence homology with pig kidney pantetheinase, vanin 1 was
identified as a pantetheinase [19].
During CoA catabolism, as illustrated in Figure 1, vanin 1 specifically hydrolyzes one of the
amide bonds of the substrate pantetheine into two products, pantothenic acid and cysteamine, which
are considered potent antioxidants [20]. The formation of pantothenic acid allows for a continuous
production of CoA, as pantothenic acid is a structural component of this cofactor. In addition,
pantothenic acid appears to have profibrotic effects, being involved in the promotion of proliferation
and migration of dermal fibroblasts [21–23]. Moreover, pantothenic acid contributes to restoring CoA
levels in the mitochondria, resulting in enhanced mitochondrial activity [24].
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Figure 1. Schematic overview of vanin 1′s enzymatic activity. Vanin 1′s substrate is pantetheine, which 
makes up the structure of coenzyme A (CoA), together with adenosine diphosphate (ADP). The 
enzyme catalyzes the hydrolysis of pantetheine into pantothenic acid and cysteamine, which in turn 
can be oxidized (Ox.) to cystamine. Pantothenic acid can be recycled as a precursor of CoA after five 
biochemical reaction steps (symbolically represented by five arrows). 
Cysteamine, an aminothiol, can be oxidized to the disulfide cystamine. This reaction is reversible 
(Figure 1). Together, cysteamine and cystamine are important sensors of oxidative stress, maintaining 
the thiol-disulfide equilibrium through protein disulfide exchange [25,26]. At low concentrations, 
cysteamine can form a complex with cysteine, promoting the latter’s transport into cells. Cysteine is 
Figure 1. Schematic overview of vanin 1′s enzymatic activity. Vanin 1′s substrate is pantetheine,
which makes up the structure of coenzyme A (CoA), together with adenosine diphosphate (ADP).
The enzyme catalyzes the hydrolysis of pantetheine into pantothenic acid and cysteamine, which in
turn can be oxidized (Ox.) to cystamine. Pantothenic acid can be recycled as a precursor of CoA after
five biochemical reaction steps (symbolically represented by five arrows).
Cysteamine, an aminothiol, can be oxidized to the disulfide cystamine. This reaction is
reversible (Figure 1). Together, cysteamine and cystamine are important sensors of oxidative stress,
maintaining the thiol-disulfide equilibrium through protein disulfide exchange [25,26]. At low
concentrations, cysteamine can form a complex with cysteine, promoting the latter’s transport into
cells. Cysteine is subsequently incorporated into the strong antioxidant glutathione (GSH) by the
enzyme γ-glutamylcysteine synthetase (γ-GCS). High concentrations of cysteamine inhibit the activity
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of glutathione peroxidase, which catalyzes the oxidation of GSH to glutathione disulfide (GSSG)
to maintain the intracellular redox homeostasis [27,28]. In addition, γ-GCS is inhibited by high
concentrations of cystamine, thus depleting the intracellular stores of GSH [29]. The role of cysteamine
and cystamine is illustrated by experiments using vnn1–deficient mice. The absence or reduced level
of cysteamine led to an enhanced γ-GCS activity and, consequently, led to elevated endogenous GSH
stores in tissues [7]. This conferred a higher resistance to oxidative stress exposure to vnn1 knockout
(KO) mice compared to wild type (WT) mice; the resistance could be abolished by administration
of cystamine, likely due to inhibition of γ-GCS through protein disulfide exchange [30,31]. As a
consequence, vnn1-KO mice were better protected against tissue inflammation in response to systemic
oxidative stress, suggesting that vanin 1 may promote inflammation.
It has been shown that vanin 1 also plays a role in the regulation of a number of metabolic
pathways. In fact, the vnn1 gene was found to be one of the positive targets of the peroxisome
proliferator-activated receptor alpha (PPAR-α) in mouse liver [4,32,33]. PPAR-α is a key regulator
of the liver’s response to fasting. It promotes uptake, utilization, and catabolism of fatty acids by
upregulation of genes involved in fatty acid transport, fatty acid activation, and peroxisomal and
mitochondrial fatty acid β-oxidation [34]. Microarray analyses showed that, upon administration of
the PPAR-α agonists fenofibrate, clofibrate, or Wy-14,643, vnn1 expression increased [35,36]. In line
with these findings, PPAR-α KO mice showed a negligible liver vnn1 expression [37,38], even after
stimulation with various agonists. [33]. Rommelaere et al. used a bioinformatics approach to confirm
PPAR-α’s regulation of vnn1 gene expression. Two candidate sites for PPAR-α response elements
(PPRE) were identified upstream of vnn1. Focusing on the proximal site, reporter assays using
constructs containing parts of the vanin 1 promoter upstream of the luciferase gene were carried out.
Following transfection, luciferase activity was significantly induced in the presence of PPAR-α agonists
when using a 3.5 kb part of the vanin 1 promoter. Sequence analysis identified two PPRE sites within
the vanin 1 promoter region. In addition, serum vanin 1 levels in the liver were shown to be regulated
by PPAR-α activity. Treatment with the PPAR-α agonist fenofibrate resulted in an increased production
of serum vanin 1 [4]. These levels of serum vanin 1 might be due to altered expression ascribed to
polymorphism in regulatory regions [39].
vnn1 has been found to directly regulate PPAR-γ mRNA expression in gut epithelial cells [40].
PPAR-γ regulates energy storage [41] and plays an important role in the innate and adaptive immune
response. This receptor has long been studied for its anti-inflammatory activity. Berruyer et al. showed
that vnn1 prevents PPAR-γ nuclear translocation; as such, the presence of vnn1 is key for the perception
of stress by innate immune cells.
PPAR-γ also controls the expression of many genes related to the regulation of adipocyte
differentiation, fatty acid (FA) storage, and glucose metabolism. In a study by Chen et al. [42], vanin 1
was shown to be an activator of hepatic gluconeogenesis in mice. Vanin 1 overexpression increased
glucose output by specifically increasing the hepatic transcription levels of gluconeogenic genes,
while vnn1 knockdown decreased the glucose output of murine hepatocytes. The transcription of
vnn1 itself was activated by PPAR-γ coactivator 1α (PGC-1α) in complex with the hepatocyte nuclear
factor-4α (HNF-4α). In turn, this complex is mediated by the Akt signaling pathway. In fact, the
insulin-Akt signaling axis plays an important role in regulating the gluconeogenesis and is activated
by PPAR-γ [26,27]. Upon PGC-1α overexpression, both in vitro and in vivo, an increased level of
vanin 1 expression at both the gene and the protein level was observed, suggesting vnn1 is a direct
target for PGC-1α. Indeed, when PGC-1α gene expression was knocked down, a decrease of vanin 1
expression in the liver and in cultured hepatocytes was observed. Thus, PGC-1α positively regulates
vnn1 gene expression, which in turn regulates gluconeogenesis. In contrast, vanin 1′s reaction products
cysteamine and pantothenic acid are involved in regulating glycolysis. Cysteamine was reported to
play a role in limiting glycolysis and lactate release [24], while pantothenic acid was linked to high
lactate release, indicating glycolytic activity [43].
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2. Vanin 1 Expression and Its Role in Diseases
In recent years, a number of studies have identified vanin 1 as a key player in the development
and continuation of diseases, in both animal models and humans. These roles of vanin 1 will be
discussed below with regard to the different organs in which the enzyme is expressed.
2.1. Liver
In both mouse and human liver, vanin 1 is expressed at the gene and protein levels [7,37,42,44,45].
The protein vanin 1 is expressed by hepatocytes, the major cell type of the liver, specifically by the
centrilobular hepatocytes in zone 3 adjacent to the central vein. These hepatocytes are involved in
lipid and xenobiotic metabolism [46]. Both processes are regulated by PPAR-α activation [47].
2.1.1. Vanin 1 in Steatosis, NAFLD, and NASH Models
Hepatic vanin 1 expression and activity were previously shown to be significantly induced by
dietary fatty acids [38]. The vnn1 gene being a target of PPAR-α [4], it comes as no surprise that oral
administration of PPAR-α agonists such as fenofibrate significantly induced vanin 1 expression [32,33].
PPAR-α contributes to liver homeostasis by limiting steatosis; however, the association of vanin 1 with
hepatic steatosis is somewhat ambiguous. Some mouse studies showed a strongly increased vanin 1
expression in high-fat diet-induced steatotic livers [37,48]. This would imply a causal role for vanin 1
in the progression of steatosis. On the other hand, Van Diepen et al. [33] observed that the presence of
vanin 1 actually protects against the development of steatosis induced by prolonged starvation in mice.
Using vnn1 KO and WT mice, they showed that vanin 1 deficiency led to an increased accumulation of
lipids and hepatic triglyceride (TG) levels in 24 h fasted livers. In addition, when rats were treated with
the vanin 1 inhibitor RR6 [49] for four days and subsequently fasted for 24 h, they showed an increased
liver weight, indicating increased hepatic steatosis. Furthermore, vanin 1 activity in human plasma
was analyzed. The activity was found to be increased by PPAR-α activation, induced by fasting or
fibrate treatment. These findings suggest that the relationship between steatosis and vanin 1 expression
may be explained by an increased activation of PPAR-α upon fasting and subsequent transcription of
its target genes in steatotic livers.
Non-alcoholic fatty liver disease (NAFLD) is characterized by an increased fat deposit in
the liver and the accumulation of saturated free fatty acids (FFAs), which contribute to disease
progression through toxic effects on hepatocytes [50]. Indeed, lipotoxicity may result in hepatocyte
damage, triggering an inflammatory reaction and an abnormal wound healing response that results
in the development of non-alcoholic steatohepatitis (NASH) and fibrosis [51,52]. Growing evidence
suggests that angiogenesis plays a central role in the progression to NASH [53–56]. During liver
fibrogenesis, hepatic stellate cells (HSCs) switch from being quiescent to activated and proliferative
myofibroblast-like cells. This activation involves up-regulation of various genes, including α-smooth
muscle actin (α-SMA), collagen-1α1, and transforming growth factor-β (TGF-β) [57]. Povero et al.
mimicked lipid accumulation that occurs in NAFLD and NASH and showed that hepatocytes secreted
microparticles (MPs), both in vitro and in vivo [44,45]. Upon internalization, these MPs promoted
angiogenesis. LC-MS/MS analysis showed that vanin 1 was one of the most abundant surface proteins
in hepatocyte-derived MPs. Next, MPs were exposed to human umbilical vein endothelial cells
(HUVECs). Since GPI-anchored proteins are often associated with lipid raft domains in the plasma
membrane, immunogold electron microscopy studies were undertaken to examine the colocalization
of vanin 1-positive MPs and HUVEC lipid rafts to assess whether the internalization of microparticles
could be promoted by vanin 1. In fact, vanin 1-positive MPs were found to be colocalized with the
HUVEC lipid rafts. To independently confirm these results, a vanin 1 neutralizing antibody was used
to block the interaction of the lipid rafts and vanin 1, and a significant reduction in MP uptake, cell
migration, and tube formation was observed. Furthermore, MPs derived from hepatocytes were found
to carry and transfer microRNAs (miRNA, e.g., miR-128-3p) that regulate fibrogenesis by inducing a
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phenotypical switch from a quiescent state to activated HSCs [45]. Proteomics analysis showed that
the MPs were enriched in vanin 1 on the external leaflet and that vanin 1 was, again, required for the
interaction with lipid raft domains. Thus, vanin 1 forms an important link between lipid accumulation
and hepatic diseases, such as fibrosis.
2.1.2. Vanin 1 and Hepatotoxicity
Vanin 1 has also been studied in relation to hepatotoxicity, for instance drug-induced toxicity.
APAP (acetyl-para-aminophenol, or paracetamol) is one of the most commonly used drugs, owing
mainly to its safety profile. However, when taken in large amounts, APAP can lead to severe necrosis
in the centrilobular hepatocytes [43,58]. It was previously demonstrated in mouse models that vanin 1
protects the liver from hepatotoxicity, specifically from APAP injury [59–61]. Mice lacking vanin 1
were shown to be sensitive to APAP hepatotoxicity and they exhibited increased concentrations
of plasma alanine aminotransferase (ALT) and more necrosis compared to WT mice. Importantly,
the susceptibility of vanin 1 KO mice to APAP hepatotoxicity was not due to a decreased capacity
of the liver to detoxify APAP via GSH, though lowered proliferative and immune responses were
observed [60]. As a consequence, compared to WT mice, less infiltration of immune cells within areas
of centrilobular necrosis was seen in vnn1 KO mice, leading to even more severe damage. Furthermore,
vanin 1 KO mice showed higher susceptibility to hepatic injury, also when other hepatotoxicants such
as carbon tetrachloride (CCl4) and concanavalin A were administered. Thus, the damage reported was
not unique to APAP. Moreover, the observation of a lowered immune response in vnn1 KO mice could
suggest a correlation between immune cells and the expression of vanin 1 [60]. Within this context,
vanin 1 seems to play a protective role when the liver is considerably injured.
Kisseleva and coworkers evaluated the origin of hepatic myofibroblasts in WT C57BL/6 mice
after chronic injury with either CCl4 or common bile duct ligation (BDL) [62]. Hepatotoxic (CCl4)
and cholestatic (BDL) injuries were shown to activate distinct subsets of fibrogenic myofibroblasts.
Interestingly, vnn1 expression also varied depending on the etiology of the hepatic injury. With the
use of a whole mouse genome microarray, vnn1 expression was found to be increased 8.5-fold in
activated portal fibroblasts (aPFs) obtained via a BDL fibrotic mouse model, compared to activated
hepatic stellate cells (aHSCs) obtained by BDL and CCl4 models [62]. These findings suggest that
vnn1 expression and regulation can strictly depend on the specific diseased liver model and, in this
particular case, also on the origin of myofibroblasts.
2.2. Kidney
In physiological conditions, mouse, rat and human vanin 1 are expressed in the brush borders of
the proximal tubuli of the nephron [7]. These proximal tubular cells are characterized by the presence
of microvilli and, therefore, they present an increased apical surface area in which many transporters
and channels are expressed [63]. The presence of vanin 1 specifically at the brush borders suggests that
vanin 1 is pivotal for the salvaging and recycling of pantothenic acid.
2.2.1. Vanin 1 in Acute Kidney Injury and Drug-Induced Renal Injury
Acute kidney injury (AKI) is a fairly common disorder, albeit with high morbidity and mortality.
In a rat ischemia-reperfusion model (bilateral renal artery clamping), alterations in the expression of
18 genes were identified by DNA microarray analysis. The vnn1 gene was one of nine genes found to
be upregulated in the early phase of AKI [64].
Hosohata et al. explored the potential of vanin 1, present at the brush borders where the first
filtration occurs, as a biomarker for nephrotoxicant-induced renal injury [65]. They used ethylene
glycol (EG) to cause nephrotoxicity in in vitro and in vivo models. EG is a well-known organic
toxic compound that causes damage to the proximal tubuli due to crystallization and consequent
obstruction [66,67]. Upon exposure to EG, vanin 1 mRNA expression and protein levels both increased
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in human renal tubular HK-2 cells and in an in vivo rat model. Moreover, in the EG-treated group,
higher concentrations of soluble vanin 1 were observed both in serum and in urine [65].
Similarly, increased urinary vanin 1 levels were observed in rats intraperitoneally injected with
cisplatin or gentamicin sulfate to induce nephrotoxicity [68]. While rats treated with EG showed higher
vanin 1 mRNA levels [65], vanin 1 mRNA expression was not increased after cisplatin and gentamicin
treatment. In addition, vnn1 gene expression was evaluated in the human proximal tubular cell line
HK-2. vnn1 expression decreased in a dose-dependent manner after 24 h exposure to gentamicin or
cisplatin. In contrast, upon exposure to EG, vnn1 gene expression increased in the same HK-2 cell
line. At the protein level, renal vanin 1 was also significantly decreased in rats treated with cisplatin
and gentamicin. Thus, these different patterns at gene and protein levels of vanin 1 may be the result
of the different mechanisms that lead to injury and toxicity. Cisplatin and gentamicin are known
to directly cause renal cell death [69,70], whereas EG causes toxicity due to the accumulation of its
metabolites. The Vanin 1 concentration in serum was found to be significantly higher in rats treated
with EG compared to the control, while in rats treated with cisplatin and gentamicin its concentration
was almost undetectable. Taken together, regardless of the toxicant causing injury, high concentrations
of vanin 1 were found in the urine in both studies described above. Therefore, these results suggest a
potential role for vanin 1 as a biomarker of renal injury.
2.2.2. Vanin 1 in a Unilateral Ureteral Obstruction Model
Hydronephrosis can be one of the causes of chronic kidney disease. This swelling of the kidney is
caused by a build-up of urine, which in turn is caused by urinary tract obstruction. Hosohata et al. [71]
investigated the potential of vanin 1 as a biomarker in a unilateral ureteral obstruction (UUO) rat
model, which is also used to develop renal fibrosis in mice and rats. On day 7 after UUO, urinary
vanin 1 levels were significantly higher than those in urine from sham-operated rats, suggesting a
potential cleavage of vanin 1 from the membrane or a higher expression of its soluble form. The levels
of urinary vanin 1 in UUO remained high until day 14. There was no significant difference in the serum
vanin 1 level between sham-operated rats and rats with UUO throughout the experiment. In kidney
tissue of UUO rats, vanin 1 protein levels were significantly decreased only on day 14, while the vanin 1
mRNA level was significantly decreased already on day 3 and 7. Again, urinary vanin 1 was marked
as a promising candidate biomarker for renal tubular injury, in this case due to hydronephrosis.
In our own work, we observed a similar downregulation of mRNA levels of vanin 1 in a UUO
mouse model (Bartucci R, Salvati A, Olinga P, Boersma YL. Regulation of vanin 1 in precision-cut tissue
slices ex vivo model as onset and end-stage disease models of fibrosis. Manuscript in preparation).
The vanin 1 mRNA level was also decreased on day 3 and 7, whereas no difference in protein expression
was observed in vanin 1 immuno-stained kidney sections of UUO mice compared to the sections
of negative control. Additionally, precision-cut kidney slices (PCKS) obtained from UUO mice and
healthy kidneys were maintained in culture for 48 h, after which downregulation of mRNA level of
vanin 1 was observed.
Miyagawa and coworkers [72] analyzed human vanin 1 in samples collected from 28 hydronephrosis
cases. In brief, they compared these 28 samples to those of 21 control patients and showed that
vanin 1 concentration was, once again, really high in renal pelvic urine. Moreover, they demonstrated
that vanin 1 and N-acetyl-β-d-glucosaminidase (NAG) were useful factors to predict hydronephrosis.
Furthermore, they also studied the possibility to use vanin 1 as a biomarker to monitor the course after
an upper urinary tract obstruction intervention and it was demonstrated that the levels of vanin 1
decreased after surgery. Thus, this pilot study demonstrates the better diagnostic value of renal pelvic
vanin 1 in human samples than kidney injury molecule-1 (KIM-1) or neutrophil gelatinase-associated
lipocalin (NGAL), commonly used as biomarkers for hydronephrosis conditions, and the potential of
vanin 1 as biomarker for AKI was again confirmed.
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2.2.3. Vanin 1 in Diabetic Nephropathy
Vanin 1 was also indicated to play a role in kidney damage in a rat model of type 1 diabetic
nephropathy (DN) [73]. Rats with streptozotocin-induced DN showed a most significant upregulation
of vanin 1 at the protein level. This upregulation of vanin 1 in type 1 diabetes (T1D) was also seen in
pooled urine of T1D patients with macroalbuminuria [74]. Nevertheless, the analysis of spot urine
from individual patients showed great variability in vanin 1 concentration, without upregulation in
DN patients.
In conclusion, these studies show that the renal expression of vanin 1, at both the gene and protein
level, is modulated differently depending on the specific etiology of the injury and potential correlation
with diseases such as diabetes. However, a common finding appears to be the significantly increased
concentration of vanin 1 in urine collected in pathophysiological conditions, highlighting vanin 1′s
potential as a valuable biomarker for renal diseases.
2.3. Intestine
Intestinal vanin 1 is mainly expressed by enterocytes at the brush border of the intestine, similar
to the renal proximal tubuli [75]. While pantothenic acid is present in most foods as part of CoA, in this
form it cannot be adsorbed by the enterocytes in the gut. However, pantothenic acid itself can easily
pass the barrier of gut epithelial cells. Therefore, the presence of vanin 1 could be explained by its
primary role to recycle Vitamin B5, which is necessary for the formation of CoA in the gut.
2.3.1. Vanin 1 in Intestinal Inflammation Models
As described above, the strict correlation between vanin 1 and oxidative stress is well known.
To assess a potential role for vanin 1 in intestinal pathologies and to examine the susceptibility
of vnn1 KO mice to intestinal inflammation, both acute and chronic infections were studied [75].
In animal models, oxidative stress in the gut can be generated by acute exposure to a nonsteroidal
anti-inflammatory drug (NSAID), such as indomethacin, or a chronic infection with Schistosoma mansoni,
a water-borne parasite. Although the Schistosoma model is largely used to better understand the
delayed hypersensitivity response in liver [76], the intestine is known to be the second main site of egg
deposition injury.
Histological examination of vnn1 KO mice treated with indomethacin showed that the integrity
and architecture of the intestinal tissue remained intact, in contrast to that of WT indomethacin-treated
mice. Furthermore, vnn1 KO mice showed less inflammation upon indomethacin treatment than WT
mice. The iNOS and COX-2 mRNA levels were higher in WT than in vnn1 KO mice.
Upon Schistosoma infection, vnn1 KO mice survived longer than WT and detailed histological
analyses showed that myeloid cell infiltration and tissue damage were more pronounced in WT than in
vnn1 KO mice. Interestingly, higher GSH levels were found in vnn1 KO mice than in WT mice. These
increased GSH levels in vnn1 KO mice could be the result of enhanced synthesis in the liver, as indicated
by an increase in γ-GCS activity. However, basal γ-GCS activity was comparable for vnn1 KO and WT
mice. In conclusion, in both models vnn1 KO mice were shown to better control and survive intestinal
inflammation and the ensuing duodenal hemorrhages that normally lead to death [75]. Collectively,
these observations point to a pro-inflammatory role of vanin 1, with its pantetheinase activity as a
major regulator of intestinal inflammation.
2.3.2. Vanin 1 in a Colitis Mouse Model
Using a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis mouse model it was reported that vanin 1
deficiency protects mice from colitis [40]. This was clearly demonstrated by an improved survival of
vnn1 KO mice compared to WT animals after TNBS treatment. A total of 70% of vnn1 KO mice survived
the first ten days of treatment, whereas 80% of the WT animals died. This protection was reversible by
administration of either cystamine or bisphenol A diglycidyl ether, a PPAR-γ antagonist. Vanin 1, by
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antagonizing PPAR-γ, licenses the production of inflammatory mediators by intestinal epithelial cells.
Again, in chronic inflammation of the intestine vanin 1 acts as pro-inflammatory agent [40].
2.3.3. Vanin 1 in Human Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a chronic inflammatory syndrome of the digestive tract, which
probably develops due to an immune system malfunction, while other factors, such as diet and stress,
can aggravate it [77,78]. Since vanin 1 has been described as a sensor of stress, controlling oxidative
stress and inflammation responses in many tissues, a role for vanin 1 in IBD was anticipated [39,79].
Not surprisingly, the vnn1 transcript was found to be increased up to 400-fold, not only in IBD
patients, but particularly in ulcerative colitis patients. Enhanced vanin 1 expression was detectable in
biopsies harvested during the quiescent phase of the disease, suggesting that the overexpression is not
necessarily correlated to inflammation. As single-nucleotide polymorphisms of vnn1 have been shown
to be important in certain pathologies before [80,81], a genetic association between vnn1 and IBD was
explored. Three single-nucleotide polymorphisms (SNPs) were found to be associated with IBD. These
regions were correlated with vnn1 transcript abundance in the colon. All in all, these findings suggest
that vanin 1 could pose as a therapeutic target or fecal biomarker in IBD.
2.4. Lungs
Whether vanin 1 plays a (patho)physiological role in lung tissue remains an unanswered question,
although vanin 1 expression in pulmonary tissue has been reported [82].
Vanin 1 in Asthma
In a recent study, vanin 1 was found to be a biomarker of corticosteroid treatment response
in children with asthma [82]. Nasal epithelial cells, known to reflect the changes that appear in
the bronchial airways in asthma patients, were sampled during asthma attacks. Genome-wide
expression profiling demonstrated that vanin 1 mRNA expression consistently discriminated between
good and poor responders to systemic corticosteroid treatment. Indeed, vanin 1 mRNA levels were
significantly lower in the poor responder group compared to the good responder group. In addition,
methylation levels at the chondroitin proteoglycan 4 (CpG4) site were significantly decreased in
poor responders, while they were increased in good responders following treatment. These findings
suggest that CpG4 methylation could regulate vanin 1 expression and, consequently, the response to
corticosteroid treatment. To corroborate these results, vnn1 KO mice were exposed to intratracheal doses
of house dust mite (HDM) to induce allergic airway inflammation and treated with intraperitoneal
dexamethasone. Airway hyperresponsiveness (AHR) was assessed after 24 h and bronchoalveolar
lavage fluid (BALF) was collected and processed. Dexamethasone treatment significantly alleviated
AHR in WT mice, as reflected by a 70% reduction in total BALF cells. In contrast, vnn1 KO mice
were unresponsive to dexamethasone treatment, demonstrating that vanin 1 contributes to an optimal
response to corticosteroid treatment in experimental asthma [82]. Importantly, vanin 1 was not essential
to asthma development, because vnn1 KO mice did develop an asthma phenotype, including airway
inflammation. However, further investigation is needed in order to better understand the specific role
of vanin 1 in the lungs and correlated diseases, such as fibrosis.
3. Conclusions
The correlation of vanin 1, via its enzymatic production of cysteamine, with oxidative stress and
consequently chronic inflammation is now well understood. Furthermore, vanin 1 partly regulates
metabolic pathways through PPAR-α and PPAR-γ, thus playing a role in specific metabolic pathways.
Vanin 1 is central in a plethora of pathological conditions, as described above in detail. Additionally,
vanin 1 also plays a role in malaria susceptibility [6], psoriasis [83], carcinogenesis [84], cardiovascular
disease [85], pediatric immune thrombocytopenia [86], and systemic sclerosis [21].
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In certain diseases vanin 1 is upregulated, contributing to the progression and severity of the
pathological status (Table 1). This raises the question of whether vanin 1 has potential as a biomarker of
disease progression. Several studies have reported that vanin 1 is a direct PPAR-α target gene and that
its serum protein level accurately reflects PPAR-α activation in the liver. In addition to the catabolism
of FFAs, PPAR-α also modulates cytoprotection, inflammation, and hepatocarcinogenesis [87]. Thus,
using serum vanin 1 as a biomarker may be of interest to monitor PPAR-α activity in liver disease.
In AKI, the potential of vanin 1 has been explored in more detail, particularly since vanin 1 is
secreted in higher concentrations in urine of patients (Table 1). As such, vanin 1 is readily available,
non-invasive, and easily measured, all characteristics of a good biomarker [88]. In addition, it was
shown that vanin 1 could be measured with high sensitivity and specificity in human renal pelvic urine
from patients with obstructive nephropathy. Furthermore, in patients receiving treatment, vanin 1
levels decreased significantly from one week after therapeutic intervention [72]. Hence, urinary vanin
1 is a promising biomarker, not only to detect, but also to monitor the clinical course of obstructive
nephropathy (Table 1). Nevertheless, the precise role of vanin 1 in renal pathologies, be it protecting
from or exacerbating inflammation, is unclear.
Table 1. Role of vanin 1 in diseases of organs in which it is highly expressed.
Organ. Disease Vanin 1
Liver
Steatosis Higher transcription of gene expression [33,38,49]
NAFLD/NASH Promoting MP uptake by HSCs andendothelial cells [44,45]
Hepatoxicity (APAP and CCl4) Protective role [59–61]
Kidneys AKI/drug-induced kidneyinjury/hydronephrosis and fibrosis/DN Urinary biomarker [64,65,68,71,72]
Intestine Intestinal inflammation/colitis/IBD Pro-inflammatory role [40,75,76]Intestinal biomarker [39]
Lungs Asthma Biomarker as discriminating factor tocorticosteroid treatment response [82]
The development of vnn1 KO mice has been pivotal for our understanding of vanin 1′s
(patho)physiological role. Though the KO mice do not have an obvious spontaneous phenotype, they
are resistant to inflammation and oxidative stress, thus indisputably proving a correlation between
vanin 1, its pantetheinase activity and pro-inflammatory mediators (Table 1) [19,59]. Vanin 1 inhibitors
have also been valuable tools in the elucidation of vanin biology. The first inhibitors showed IC50 values
between 4–20 µM; however, their specificity was rather low [89]. Schalkwijk and coworkers developed
a pantetheine analog, RR6, which showed high specificity towards vanin 1 [90]. The compound
competitively and reversibly inhibited pantetheinase activity at nanomolar concentration; its potency
was also confirmed in in vivo rat models [33,49,91]. Though further in-depth studies are warranted to
specify the relevance of vanin 1 inhibition, compound RR6 certainly forms an exciting starting point to
advance our knowledge of vanin biology and may lead to new therapeutic anti-inflammatory strategies.
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